Inotsume N, Higashi A, Matsukane I, Chikazawa S, Nakano M, Matsuda I
Pediatr Pharmacol (New York). 1986;5(4):253-9.
Serum concentration of dantrolene and its active metabolite, 5-hydroxydantrolene were determined in 27 cerebral palsy patients. Correlation coefficients between the oral dose of dantrolene and serum levels of dantrolene and its major metabolite, 5-hydroxydantrolene were rather small in cerebral palsy patients. The mean half-times of dantrolene and 5-hydroxydantrolene were 3.41 (n = 6) and 4.00 (n = 5) hours, respectively. These values were about a half of those reported earlier [Lietman et al., 1974; Meyler et al., 1979; Flewellen et al., 1983]. The poor correlation between serum level and dose may be due to the variation in an extent of oral dantrolene availability.
测定了27例脑瘫患者的丹曲林及其活性代谢物5-羟基丹曲林的血清浓度。在脑瘫患者中,丹曲林口服剂量与丹曲林及其主要代谢物5-羟基丹曲林血清水平之间的相关系数相当小。丹曲林和5-羟基丹曲林的平均半衰期分别为3.41小时(n = 6)和4.00小时(n = 5)。这些值约为先前报道值的一半[利特曼等人,1974年;迈勒等人,1979年;弗莱韦伦等人,1983年]。血清水平与剂量之间相关性较差可能是由于口服丹曲林可用性程度的差异。